Strategies presented to avoid overzealous lung CA screening

June 24, 2014
Strategies presented to avoid overzealous lung CA screening

(HealthDay)—The benefits and harms of low-dose computed tomography (LDCT) screening for lung cancer should be carefully considered before Medicare decides on its coverage policy, according to an editorial published online June 24 in the Annals of Internal Medicine.

Noting that on April 30, 2014, the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) gave a vote of low confidence in the benefits versus harms of LDCT screening, Renda Soylemez Wiener, M.D., M.P.H., from Boston University School of Medicine, discussed Medicare's options for coverage.
The author notes that LDCT screening can be safely and effectively implemented in the community using carefully designed screening programs with precautions to minimize harms and maximize benefits. The implications of the MEDCAC vote could mean that LDCT will not be covered by the Centers for Medicare and Medicaid Services (CMS), which would potentially increase the socioeconomic- and age-based disparities in outcomes. An alternative approach would be a CMS determination of coverage during a period of evidence development. Perhaps an optimal option would be for CMS to offer LDCT screening coverage when conducted in certified facilities that provide comprehensive, patient-centered programs, designed to maximize and minimize harms.

"To avoid the hard lessons learned from overzealous implementation of prostate cancer screening, we must get implementation of LDCT screening right from the outset," the author writes.

Explore further: Low-dose CT screening may benefit individuals at increased risk for lung cancer

More information: Editorial

Related Stories

Recommended for you

Shape of tumor may affect whether cells can metastasize

April 28, 2016

Only a few cells in a cancerous tumor are able to break away and spread to other parts of the body, but the curve along the edge of the tumor may play a large role in activating these tumor-seeding cells, according to a new ...

SPF30 sunscreens delay melanoma incidence in preclinical model

April 18, 2016

Application of sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model of the disease, according to data from a team at The Ohio State University Comprehensive ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.